Kinnate Biopharma Inc.

KNTE · NASDAQ
Analyze with AI
12/31/2023
9/30/2023
6/30/2023
3/31/2023
Operating Activities
Net Income-$17-$31-$32-$33
Dep. & Amort.$0$0$0$0
Deferred Tax-$8$4$4$0
Stock-Based Comp.$4$5$5$5
Change in WC-$3$1-$2$0
Other Non-Cash$7-$5-$5-$1
Operating Cash Flow-$17-$26-$29-$28
Investing Activities
PP&E Inv.$0$0$0-$0
Net Acquisitions-$9$0$0-$0
Inv. Purchases-$19-$29-$73-$33
Inv. Sales/Matur.$42$72$62$89
Other Inv. Act.$0$0-$0$0
Investing Cash Flow$14$43-$11$55
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$0$1$0
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$9$0$1-$9
Financing Cash Flow$9$0$1-$9
Forex Effect$0-$12$44$0
Net Chg. in Cash$5$17-$39$19
Supplemental Information
Beg. Cash$52$35$74$55
End Cash$57$52$35$74
Free Cash Flow-$17-$26-$29-$28
Kinnate Biopharma Inc. (KNTE) Financial Statements & Key Stats | AlphaPilot